Jazz Pharmaceuticals (JAZZ) AI Stock Analysis

• Market Cap: $10.38B
• Dividend Yield: N/A
• Average Volume (3M): 1.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 4.14%
• EPS Growth: -179.96%
• Country: US
• Employees: 2,800
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 8.13
• Shares Outstanding: 60,765,118
• 10 Day Avg. Volume: 1,085,116
• 30 Day Avg. Volume: 1,388,106
• PEG Ratio: 0.35
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 5.65
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 2.77
• Enterprise Value/Gross Profit: 3.24
• Enterprise Value/Ebitda: 44.67
• 1Y Price Target: $211.60
• Price Target Upside: 23.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): 7.91
• Revenue Forecast (FY): $4.22B

• Rating: 64 Neutral
• Price Target: $182.00 ▲(6.56% Upside)

Jazz Pharmaceuticals' overall score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance challenges and valuation concerns weigh on the score.

Positive Factors

Pipeline Strength

The successful trial results for Ziihera enhance Jazz's oncology portfolio, potentially leading to new market opportunities and revenue streams.

Revenue Growth

Record revenues indicate strong product demand and successful new product launches, supporting long-term growth potential.

Strategic Advancements

Strategic advancements, including FDA approvals, position Jazz for sustainable growth and competitive advantage in its markets.

Negative Factors

Profitability Challenges

Negative margins and declining ROE indicate operational inefficiencies, which could hinder long-term financial stability and growth.

Generic Competition

The potential entry of generics poses a threat to revenue from key products, potentially impacting Jazz's market share and profitability.

Declining Sales

Declining sales of Zepzelca reflect competitive pressures, which may affect Jazz's revenue growth and market position in the oncology sector.

Jazz Pharmaceuticals Business Overview & Revenue Model

Company Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Jazz Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, with key revenue streams coming from its established drugs in the neuroscience and sleep medicine sectors. The company has a strong focus on research and development, which contributes to the introduction of new products and the expansion of its existing drug portfolio. Additionally, Jazz engages in strategic partnerships and collaborations with other pharmaceutical companies and research organizations, enhancing its ability to innovate and market new therapies. The company also benefits from licensing agreements and royalties related to its products, further diversifying its income sources.

Jazz Pharmaceuticals Financial Statement Overview

Summary

Jazz Pharmaceuticals faces profitability challenges with negative margins and a declining return on equity, but shows improvement in leverage and stable cash flow.

Income Statement

Jazz Pharmaceuticals shows a mixed performance in its income statement. The TTM data indicates a slight revenue growth of 1.74%, but the company is currently facing profitability challenges with a negative net profit margin of -8.86% and a negative EBIT margin of -10.29%. This is a significant decline from the previous year's positive margins, indicating potential operational inefficiencies or increased costs.

Balance Sheet

The balance sheet reveals a moderate financial position. The debt-to-equity ratio has improved to 0.27 in the TTM, indicating reduced leverage compared to previous years. However, the return on equity is negative at -9.25%, reflecting the company's current unprofitability. The equity ratio remains stable, suggesting a balanced asset structure.

Cash Flow

Cash flow analysis shows a positive trend with a free cash flow growth rate of 5.65% in the TTM. The operating cash flow to net income ratio is 0.61, indicating that the company generates sufficient cash flow relative to its net income, despite the latter being negative. The free cash flow to net income ratio is strong at 0.96, highlighting effective cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.16B	4.07B	3.83B	3.66B	3.09B	2.36B
Gross Profit	3.55B	3.62B	3.40B	3.12B	2.65B	2.21B
EBITDA	257.52M	1.52B	1.45B	1.47B	1.03B	1.04B
Net Income	-368.48M	560.12M	414.83M	-224.06M	-328.95M	238.62M
Balance Sheet
Total Assets	11.36B	12.01B	11.39B	10.84B	12.30B	6.54B
Cash, Cash Equivalents and Short-Term Investments	2.05B	2.99B	1.63B	881.48M	591.45M	2.13B
Total Debt	5.43B	6.16B	5.79B	5.81B	6.15B	2.25B
Total Liabilities	7.40B	7.92B	7.66B	7.75B	8.33B	2.88B
Stockholders Equity	3.96B	4.09B	3.74B	3.09B	3.97B	3.66B
Cash Flow
Free Cash Flow	1.34B	1.35B	1.07B	773.78M	732.98M	520.39M
Operating Cash Flow	1.39B	1.40B	1.09B	1.27B	778.51M	899.65M
Investing Cash Flow	-1.33B	-508.19M	-163.06M	-446.23M	-5.21B	-1.01B
Financing Cash Flow	-957.10M	20.52M	-305.25M	-529.49M	3.97B	528.07M

Jazz Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 170.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 170.8 is above the 20-day moving average (MA) of 168.58, above the 50-day MA of 155.22, and above the 200-day MA of 127.16, indicating a bullish trend. The MACD of 3.15 indicates Positive momentum. The RSI at 60.01 is Neutral, neither overbought nor oversold. The STOCH value of 75.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.

Jazz Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	76 Outperform	$8.79B	95.51	16.47%	―	17.92%	-26.13%
HALO	73 Outperform	$8.04B	14.38	124.50%	―	31.19%	59.01%
JAZZ	64 Neutral	$10.38B	-28.14	-9.06%	―	4.14%	-179.96%
TECH	64 Neutral	$9.22B	120.99	3.80%	0.54%	3.85%	-48.17%
ROIV	58 Neutral	$15.65B	-40.72	-14.73%	―	-83.82%	-109.22%
RVMD	52 Neutral	$15.70B	-15.67	-60.76%	―	-100.00%	-44.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jazz Pharmaceuticals Corporate Events

Jazz Pharmaceuticals Announces Positive Phase 3 Trial Results

On November 17, 2025, Jazz Pharmaceuticals announced positive results from the Phase 3 HERIZON-GEA-01 trial, which evaluated Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival and overall survival compared to the standard treatment, trastuzumab plus chemotherapy. These findings suggest that Ziihera could become the new standard of care for this patient group, and Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026.

Jazz Pharmaceuticals Appoints Dr. Ted Love to Board

On October 23, 2025, Jazz Pharmaceuticals announced the appointment of Dr. Ted Love to its board of directors, effective December 1, 2025. Dr. Love will serve as a Class I director until the 2027 annual general meeting and will join the Audit and Science and Medicine Committees. Concurrently, Kenneth W. O’Keefe announced his retirement from the board, effective December 1, 2025, with no disputes influencing his decision.

Jazz Pharmaceuticals Settles Disputes with Avadel

On October 21, 2025, Jazz Pharmaceuticals and its subsidiaries reached a global settlement agreement with Avadel Pharmaceuticals to resolve all disputes, including ongoing patent infringement litigation. As part of the settlement, Jazz will grant Avadel licenses for its Lumryz product, while Avadel will pay royalties to Jazz and refrain from marketing certain products until 2028. Jazz will pay Avadel $90 million and waive certain royalties, expecting a pre-tax charge of approximately $90 million in Q3 2025. The agreement aims to dismiss pending legal proceedings and includes mutual releases of claims.